OncoSec Medical Incorporated (ONCS)

NASDAQ: ONCS · IEX Real-Time Price · USD
2.26
-0.38 (-14.39%)
At close: Mar 28, 2023, 4:00 PM
2.31
+0.05 (2.21%)
Pre-market: Mar 29, 2023, 5:36 AM EDT
-14.39%
Market Cap 6.72M
Revenue (ttm) n/a
Net Income (ttm) -29.39M
Shares Out 2.97M
EPS (ttm) -15.28
PE Ratio n/a
Forward PE 8.67
Dividend n/a
Ex-Dividend Date n/a
Volume 936,717
Open 1.94
Previous Close 2.64
Day's Range 1.78 - 2.29
52-Week Range 0.74 - 31.68
Beta 1.77
Analysts Sell
Price Target 5.10 (+125.66%)
Earnings Date Mar 14, 2023

About ONCS

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 40
Stock Exchange NASDAQ
Ticker Symbol ONCS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ONCS stock is "Sell." The 12-month stock price forecast is $5.1, which is an increase of 125.66% from the latest price.

Price Target
$5.1
(125.66% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Why is OncoSec Medical (ONCS) Stock Up 91% Today?

OncoSec Medical (NASDAQ: ONCS) stock is rising higher on Wednesday after the company withdrew a public stock offering. According to the company, it no longer wants to move forward with the offering.

3 weeks ago - InvestorPlace

Why Is OncoSec Medical (ONCS) Stock Down 25% Today?

OncoSec Medical (NASDAQ: ONCS) stock is falling on Thursday after the company revealed details of a stock offering. The biggest news from the company's prospectus is warrants of its stock having an e...

1 month ago - InvestorPlace

Top 5 most-shorted stocks as of December 2022

More investors are interested in shorting and learning how they might benefit from a short squeeze as a result of the Reddit-fueled short squeeze on stocks like GameStop (NYSE: GME) and AMC Theaters (...

Other symbols: CVNADBGIMULNBBBY
3 months ago - Finbold

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

PENNINGTON, N.J. and SAN DIEGO , Dec. 5, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...

4 months ago - PRNewsWire

OncoSec Announces Pricing of $3.5 Million Public Offering

PENNINGTON, N.J. and SAN DIEGO , Nov. 30, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing in...

4 months ago - PRNewsWire

ONCS Stock Alert: What to Know About OncoSec Medical as It Drops Today

Low-float stocks can do strange and unexpected things sometimes. That's as valid an explanation as any for the unusual price movement in OncoSec Medical (NASDAQ: ONCS) stock today.

4 months ago - InvestorPlace

OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma

PENNINGTON, N.J. and SAN DIEGO , Nov. 15, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical stage biotechnology company developing intratumoral ...

4 months ago - PRNewsWire

OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

PENNINGTON, N.J. and SAN DIEGO , Nov. 11, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company developing intratumoral ...

4 months ago - PRNewsWire

OncoSec Announces Reverse Stock Split

PENNINGTON, N.J. and SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...

5 months ago - PRNewsWire

OncoSec Announces Pipeline Prioritization and Workforce Reduction

PENNINGTON, N.J. and SAN DIEGO , Oct. 4, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...

6 months ago - PRNewsWire

Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research

Results demonstrate novel synergistic effects of IL-12 and T cell receptor signaling in anti-tumor immunity PENNINGTON, N.J. and SAN DIEGO , June 24, 2022 /PRNewswire/ -- OncoSec Medical Incorporated ...

9 months ago - PRNewsWire

OncoSec Receives Triple Negative Breast Cancer Foundation's Vanguard Award for Excellence in Oncology Research

PENNINGTON, N.J. and SAN DIEGO , May 23, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it is the recipient of the 2022 Vanguard Awa...

11 months ago - PRNewsWire

OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer

PENNINGTON, N.J. and SAN DIEGO , April 29, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing i...

11 months ago - PRNewsWire

OncoSec Announces Appointment of George Chi as Chief Financial Officer

PENNINGTON, N.J. and SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing int...

1 year ago - PRNewsWire

OncoSec Announces Changes to its Board of Directors

PENNINGTON, N.J. and SAN DIEGO, Dec. 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...

1 year ago - PRNewsWire

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:...

1 year ago - PRNewsWire

OncoSec Provides Business Update

PENNINGTON, N.J. and SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a clinical-stage biotechnology company focused on developing cyt...

1 year ago - PRNewsWire

OncoSec Provides Leadership Update

PENNINGTON, N.J. and SAN DIEGO, Aug. 16, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the establishment of a Leadership Committee consis...

1 year ago - PRNewsWire

OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference

PENNINGTON, N.J. and SAN DIEGO, July 26, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Interim CEO and Chief Operating Officer, Bria...

1 year ago - PRNewsWire

Why Shares Of OncoSec Medical Are Trading Higher Today

OncoSec Medical (NASDAQ: ONCS) shares are trading higher after the company announced it entered into a Clinical Trial Collaboration and Supply Agreement with Merck to evaluate the combination of OncoS...

1 year ago - Benzinga

OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma

PENNINGTON, N.J. and SAN DIEGO, July 6, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it has entered into a Clinical Trial Collaboration ...

1 year ago - PRNewsWire

OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer

PENNINGTON, N.J. and SAN DIEGO, June 24, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that Daniel O'Connor has resigned and that Brian L...

1 year ago - PRNewsWire

OncoSec Appoints Industry Leading Electroporation Device Expert, Jeffrey Silverman, as Vice President of Product Engineering

PENNINGTON, N.J. and SAN DIEGO, June 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), today announced the appointment of Jeffrey Silverman as Vice Pres...

1 year ago - PRNewsWire

OncoSec to Present at the Raymond James Human Health Innovation Conference

PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at ...

1 year ago - PRNewsWire

OncoSec Appoints Robert M. Schinagl, Ph.D.

PENNINGTON, N.J. and SAN DIEGO, May 17, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Robert M.

2 years ago - PRNewsWire